Effects of rosuvastatin on electronegative LDL as characterized by capillary isotachophoresis: The ROSARY Study

Journal of Lipid Research

Volumn 50, Issue 9, 2009, Pages 1832-1841

  Zhang, Bo ^a   Matsunaga, Akira ^a   Rainwater, David L ^b   Miura, Shin Ichiro ^a   Noda, Keita ^a   Nishikawa, Hiroaki ^a   Uehara, Yoshinari ^a   Shirai, Kazuyuki ^a   Ogawa, Masahiro ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Hypercholesterolemia; LDL particle concentrations; Small dense LDL; Statins

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN C2; APOLIPOPROTEIN E; ATORVASTATIN; CHOLESTEROL; FAST MIGRATING LOW DENSITY LIPOPROTEIN CHOLESTEROL; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PRAVASTATIN; REMNANT LIKE PARTICLE CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN; SLOW DENSE FAST MIGRATING LOW DENSITY LIPOPROTEIN CHOLESTEROL; SLOW DENSE LOW DENSITY LIPOPROTEIN CHOLESTEROL; SLOW DENSE VERY FAST MIGRATING LOW DENSITY LIPOPROTEIN CHOLESTEROL; SLOW MIGRATING LOW DENSITY LIPOPROTEIN CHOLESTEROL; UNCLASSIFIED DRUG; VERY FAST MIGRATING LOW DENSITY LIPOPROTEIN CHOLESTEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CAPILLARY ISOTACHOPHORESIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; ISOTACHOPHORESIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PARTICLE SIZE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TREATMENT DURATION;

APOLIPOPROTEINS; BIOLOGICAL MARKERS; CHOLESTEROL; CHOLESTEROL, HDL; CORONARY DISEASE; ELECTROPHORESIS, CAPILLARY; FEMALE; FLUOROBENZENES; HUMANS; HYPERCHOLESTEROLEMIA; INFLAMMATION; LIPOPROTEINS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PYRIMIDINES; RISK FACTORS; SULFONAMIDES; TRIGLYCERIDES;

EID: 70350370464     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M800523-JLR200     Document Type: Article

References (39)

1. Grundy, S. M., J. I. Cleeman, C. N. Merz, H. B. Brewer, Jr., L. T. Clark, D. B. Hunninghake, R. C. Pasternak, S. C. Smith, Jr., and N. J. Stone. 2004. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 110: 227-239.
2. Kinlay, S. 2007. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J. Am. Coll. Cardiol. 49: 2003-2009.
3. Mora, S., and P. M. Ridker. 2006. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) - can C-reactive protein be used to target statin therapy in primary prevention? Am. J. Cardiol. 97: 33A-41A.
4. Hirano, T., Y. Ito, S. Koba, M. Toyoda, A. Ikejiri, H. Saegusa, J. Yamazaki, and G. Yoshino. 2004. Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler. Thromb. Vasc. Biol. 24: 558-563.
5. Holvoet, P., J. Vanhaecke, S. Janssens, F. Van de Werf, and D. Collen. 1998. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation. 98: 1487-1494.
6. Sanchez-Quesada, J. L., S. Benitez, and J. Ordonez-Llanos. 2004. Electronegative low-density lipoprotein. Curr. Opin. Lipidol. 15: 329-335.
7. Sanchez-Quesada, J. L., S. Benitez, C. Otal, M. Franco, F. Blanco-Vaca, and J. Ordonez-Llanos. 2002. Density distribution of electronegative LDL in normolipemic and hyperlipemic subjects. J. Lipid Res. 43: 699-705.
8. Sanchez-Quesada, J. L., M. Camacho, R. Anton, S. Benitez, L. Vila, and J. Ordonez-Llanos. 2003. Electronegative LDL of FH subjects: chemical characterization and induction of chemokine release from human endothelial cells. Atherosclerosis. 166: 261-270.
9. Benitez, S., A. Perez, J. L. Sanchez-Quesada, A. M. Wagner, M. Rigla, R. Arcelus, O. Jorba, and J. Ordonez-Llanos. 2007. Electronegative low-density lipoprotein subfraction from type 2 diabetic subjects is proatherogenic and unrelated to glycemic control. Diabetes Metab. Res. Rev. 23: 26-34.
10. Oliveira, J. A., A. Sevanian, R. J. Rodrigues, E. Apolinario, and D. S. Abdalla. 2006. Minimally modified electronegative LDL and its autoantibodies in acute and chronic coronary syndromes. Clin. Biochem. 39: 708-714.
11. Benitez S, Camacho M, Bancells C, Vila L, Sanchez-Quesada JL, Ordonez-Llanos J. Wide proinflammatory effect of electronegative low-density lipoprotein on human endothelial cells assayed by a protein array. Biochim. Biophys. Acta. 2006;1761: 1014-1021.
12. De Castellarnau, C., C. Bancells, S. Benitez, M. Reina, J. Ordonez-Llanos, and J. L. Sanchez-Quesada. 2007. Atherogenic and inflammatory profile of human arterial endothelial cells (HUAEC) in response to LDL subfractions. Clin. Chim. Acta. 376: 233-236.
13. De Castellarnau, C., J. L. Sanchez-Quesada, S. Benitez, R. Rosa, L. Caveda, L. Vila, and J. Ordonez-Llanos. 2000. Electronegative LDL from normolipemic subjects induces IL-8 and monocyte chemotactic protein secretion by human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 20: 2281-2287.
14. Gaubatz, J. W., B. K. Gillard, J. B. Massey, R. C. Hoogeveen, M. Huang, E. E. Lloyd, J. L. Raya, C. Y. Yang, and H. J. Pownall. 2007. Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A(2). J. Lipid Res. 48: 348-357.
15. Benitez, S., V. Villegas, C. Bancells, O. Jorba, F. Gonzalez-Sastre, J. Ordonez-Llanos, and J. L. Sanchez-Quesada. 2004. Impaired binding affinity of electronegative low-density lipoprotein (LDL) to the LDL receptor is related to nonesterified fatty acids and lysophosphatidylcholine content. Biochemistry. 43: 15863-15872.
16. Böttcher, A., J. Schlosser, F. Kronenberg, H. Dieplinger, G. Knipping, K. J. Lackner, and G. Schmitz. 2000. Preparative free-solution isotachophoresis for separation of human plasma lipoproteins: apolipoprotein and lipid composition of HDL subfractions. J. Lipid Res. 41: 905-915.
17. Schmitz, G., C. Mollers, and V. Richter. 1997. Analytical capillary isotachophoresis of human serum lipoproteins. Electrophoresis. 18: 187-1813.
18. Zhang, B., T. Kaneshi, T. Ohta, and K. Saku. 2005. Relation between insulin resistance and fast-migrating LDL subfraction as characterized by capillary isotachophoresis. J. Lipid Res. 46: 2265-2277.
19. Zhang, B., Y. Uehara, S. Hida, S. I. Miura, D. L. Rainwater, M. Segawa, K. Kumagai, K. A. Rye, and K. Saku. 2007. Effects of apoA-I/ phosphatidylcholine discs on charge-based LDL subfractions as characterized by capillary isotachophoresis. J. Lipid Res. 48: 1175-1189.
20. Zhang, B., N. Maeda, K. Okada, M. Tatsukawa, Y. Sawayama, A. Matsunaga, K. Kumagai, S. Miura, T. Nagao, J. Hayashi, et al. 2006. Association between fast-migrating low-density lipoprotein subfraction as characterized by capillary isotachophoresis and intimamedia thickness of carotid artery. Atherosclerosis. 187: 205-212.
21. Zhang, B., A. Matsunaga, K. Saku, S. Nakano, and T. Yamada. 2004. Associations among plasma lipoprotein subfractions as characterized by analytical capillary isotachophoresis, apolipoprotein E phenotype, Alzheimer disease, and mild cognitive impairment. Arterioscler. Thromb. Vasc. Biol. 24: e144-e146.
22. Zhang, B., A. Böttcher, S. Imaizumi, K. Noda, G. Schmitz, and K. Saku. 2007. Relation between charge-based apolipoprotein B-containing lipoprotein subfractions and remnant-like particle cholesterol levels. Atherosclerosis. 191: 153-161.
23. Zhang, B., S. I. Miura, D. Yanagi, K. Noda, H. Nishikawa, A. Matsunaga, K. Shirai, A. Iwata, K. Yoshinaga, H. Adachi, et al. 2008. Reduction of charge-modified LDL by statin therapy in patients with CHD or CHD risk factors and elevated LDL-C levels: the SPECIAL Study. Atherosclerosis. 201: 353-359.
24. Nauck, M., G. R. Warnick, and N. Rifai. 2002. Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. Clin. Chem. 48: 236-254.
25. Zhang, B., S. Eto, P. Fan, C. Bian, E. Shimoji, T. Saito, and K. Saku. 2003. Paraoxonase (Pon1) Q192R polymorphism and serum Pon1 activity in diabetic patients on maintenance hemodialysis. Clin. Nephrol. 60: 257-265.
26. Zhang, B., P. Fan, E. Shimoji, H. Itabe, S. Miura, Y. Uehara, A. Matsunaga, and K. Saku. 2006. Modulating effects of cholesterol feeding and simvastatin treatment on platelet-activating factor acetylhydrolase activity and lysophosphatidylcholine concentration. Atherosclerosis. 186: 291-301.
27. Zhang, B., P. Fan, E. Shimoji, H. Xu, K. Takeuchi, C. Bian, and K. Saku. 2004. Inhibition of cholesteryl ester transfer protein activity by JTT-705 increases apolipoprotein E-containing high-density lipoprotein and favorably affects the function and enzyme composition of high-density lipoprotein in rabbits. Arterioscler. Thromb. Vasc. Biol. 24: 1910-1915.
28. Rainwater, D. L., L. J. Martin, and A. G. Comuzzie. 2001. Genetic control of coordinated changes in HDL and LDL size phenotypes. Arterioscler. Thromb. Vasc. Biol. 21: 1829-1833.
29. Rainwater, D. L., P. H. Moore, Jr., and I. O. Gamboa. 2004. Improved method for making nondenaturing composite gradient gels for the electrophoretic separation of lipoproteins. J. Lipid Res. 45: 773-775.
30. Rainwater, D. L., P. H. Moore, Jr., W. R. Shelledy, T. D. Dyer, and S. H. Slifer. 1997. Characterization of a composite gradient gel for the electrophoretic separation of lipoproteins. J. Lipid Res. 38: 1261-1266.
31. Tsimikas, S., J. T. Willerson, and P. M. Ridker. 2006. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J. Am. Coll. Cardiol. 47: C19-C31.
32. Ansell, B. J., M. Navab, S. Hama, N. Kamranpour, G. Fonarow, G. Hough, S. Rahmani, R. Mottahedeh, R. Dave, S. T. Reddy, et al. 2003. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 108: 2751-2756.
33. Ansell, B. J., K. E. Watson, A. M. Fogelman, M. Navab, and G. C. Fonarow. 2005. High-density lipoprotein function recent advances. J. Am. Coll. Cardiol. 46: 1792-1798.
34. Benitez, S., M. Camacho, R. Arcelus, L. Vila, C. Bancells, J. Ordonez-Llanos, and J. L. Sanchez-Quesada. 2004. Increased lysophosphatidylcholine and non-esterified fatty acid content in LDL induces chemokine release in endothelial cells. Relationship with electronegative LDL. Atherosclerosis. 177: 299-305.
35. Benitez, S., J. Ordonez-Llanos, M. Franco, C. Marin, E. Paz, J. Lopez-Miranda, C. Otal, F. Perez-Jimenez, and J. L. Sanchez-Quesada. 2004. Effect of simvastatin in familial hypercholesterolemia on the affinity of electronegative low-density lipoprotein subfractions to the low-density lipoprotein receptor. Am. J. Cardiol. 93: 414-420.
36. Ooyen, C., A. Zecca, A. M. Bersino, and A. L. Catapano. 1999. NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from Hep G2 cells. Atherosclerosis. 145: 87-95.
37. Suzuki, H., H. Yamazaki, T. Aoki, J. Kojima, T. Tamaki, F. Sato, M. Kitahara, and Y. Saito. 2000. Lipid-lowering and antiatherosclerotic effect of NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in Watanabe heritable hyperlipidemic rabbits. Arzneimittelforschung. 50: 995-1003.
38. Fan, P., B. Zhang, S. Kuroki, and K. Saku. 2004. Pitavastatin, a potent hydroxymethylglutaryl coenzyme a reductase inhibitor, increases cholesterol 7 alpha-hydroxylase gene expression in HepG2 cells. Circ. J. 68: 1061-1066.
39. Navab, M., S. Y. Hama, C. J. Cooke, G. M. Anantharamaiah, M. Chaddha, L. Jin, G. Subbanagounder, K. F. Faull, S. T. Reddy, N. E. Miller, et al. 2000. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J. Lipid Res. 41: 1481-1494.